Abstract:
A process for acylating pyrrole compounds comprising reacting an aroyl halide with the pyrrole compound in the presence of an alkyl aluminum halide. Such acylated pyrrole derivatives are useful as intermediates for the preparation of anti-inflammatory agents and as synthetic intermediates.
Abstract:
Pyrryl-2-acetonitriles corresponding to the formula ##STR1## in which R.sub.1 stands for hydrogen or an alkyl group having 1-4 carbon atoms prepared from dialkyl-(pyrryl-2-methyl)-amine corresponding to the formula ##STR2## in which R.sub.1 is defined as above and R.sub.2 and R.sub.3 stand for alkyl groups having 1-4 carbon atoms, are alkylated with alkyl halides such as methyl chloride or methyl bromide to form the corresponding trialkyl-(pyrryl-2-methyl)-ammonium chloride quaternary salts and then reacted with an aqueous solution of alkali cyanide in the presence of a water-immiscible solvent under conditions which provide more economical utilization of reactants and process equipment.
Abstract:
Ascorbic acid and substituted ascorbic acids can be reacted with a tetraorganosilicate such as a tetraalkylorthosilicate to yield a product which contains silicon. The products are generally solid in nature, and typically they are insoluble without hydrolysis. The products are useful as active agents in the prevention, treatment, or delaying of the onset of calcium-related bone disease such as post-menopausal osteoporosis.
Abstract:
A process for preparing a mixed anhydride acylating agent and a process for acylating pyrrole derivatives, such as 1-methylpyrrole-2-acetonitrile using the mixed anhydride acylating agent.
Abstract:
A composition containing a zeolite and an acid suitable for use in increasing bone strength in an animal having a bone strength less than desired and/or for use in treating, preventing or delaying the onset of a bone disorder such as osteoporosis, osteochondrosis, or dyschondroplasia. A preferred zeolite is zeolite A. Preferred acids are illustrated by citric, fumaric and aspartic acids. The presence of such acids in the composition enhances the breakdown (i.e. decomposition) of the zeolite thereby making it more efficacious for increasing bone strength or combating bone disease. Preferably, the compositions contain from about 35 to about 65 weight percent of the acid; the remainder being the zeolite Such compositions can be admixed with other materials such as excipients used in the preparation of unit dosage forms.
Abstract:
Silicic acid modulates (i.e. enhances or inhibits) adenylate cycloase activity. This effect appears to be a general one, inasmuch as the modulation has occurred in all tissues studied. The results suggest that silicic acid can be used in human and veterinary medicine to modulate hormone or neurotransmitter response. The results also indicate that silicic acid can be used to prevent, treat, or delay the onset of calcium-related bone disease, or to improve bone strength in an vertebrate having a bone strength less than desired.
Abstract:
An aluminoxanate composition which can be used as a co-catalyst with transition, lanthanide or actinide metal compounds such as metallocenes comprises the solid reaction product of an aluminoxane and an alkali metal, alkaline earth metal, ammonium, phosphonium or sulfonium salt of a Group 13 to 16 element-containing polyoxy compound such as sodium aluminate.
Abstract:
It is disclosed that citric acid and salts thereof are readily produced by reacting acetone dicarboxyl ions, cyanide ions and alkali metal ions to produce an intermediate system which is subsequently reacted in an excess caustic system to form a salt of citric acid and that the salt is readily recovered by precipitation from the excess caustic system under proper conditions of concentration and temperature without requiring the formation of calcium salts. The recovered salt may be used directly or may be subjected to additional purification or may be converted to citric acid or other salts thereof by treatment with an acidification system such as sulfuric acid.
Abstract:
A process for preparing a mixed anhydride acylating agent and a process for acylating pyrrole derivatives, such as, 1-methylpyrrole-2-acetonitrile using the mixed anhydride acylating agent.
Abstract:
Novel aluminum-containing compositions having increased paraffin-solubility are produced from a methylaluminoxane composition having lower paraffin-solubility. These compositions are formed by mixing in liquid phase (A) at least one aluminum trialkyl (or solution or suspension formed therefrom), where the aluminum trialkyl has at least 30 carbon atoms in the molecule, where each alkyl group thereof is bifurcated in the 2-position into a pair of branches, where one such branch has n carbon atoms and the other such branch has at least n+2 carbon atoms, and where n is at least 3; and (B) at least one methylaluminoxane composition having lower heptane-solubility (or a solution or slurry formed therefrom). Preferably, the resultant mixture is agitated at one or more elevated temperatures at which the mixture becomes even more homogeneous. The aluminum trialkyl preferably is one or more in which there are at least 36 carbon atoms in the molecule, in which n is at least 4 and in which the longer branch of the bifurcated alkyl groups has n+2 carbon atoms.